Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

NCT07361471 | Recruiting

• 1 other identifier: 2025-A01107-42
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

Conditions

Ovarian Cancer

Keywords

ovarian cancer; long responder

Outcome Measures

Primary Outcomes (1)

• Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.

  Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.

  Through study completion, an average of 1 year

Secondary Outcomes (4)

• Phenotypic criteria differences between refactory patients and long responder patients

  Through study completion, an average of 1 year

• Clinical criteria differences between refactory patients and long responder patients

  Through study completion, an average of 1 year

• Biological criteria difference between refactory patients and long responder patients

  Through study completion, an average of 1 year

• Histological criteria differences between refactory patient and long responder patients

  Through study completion, an average of 1 year

Study Arms (1)

long-term responders

EXPERIMENTAL

molecular analysis on histological blocks

Genetic: molecular analysis

Interventions

molecular analysis GENETIC

molecular analysis on histological blocks

long-term responders

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
• Corresponding to one of the two groups below:
• Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
• Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
• Affiliation to a social security scheme
• Patient who signed the genetic consent form

You may not qualify if:

• Minor patient
• Pregnant patient
• Patient under guardianship or conservatorship
• Patients who object to the collection of their medical/paramedical data
• Patient for whom the center does not have biological material for genomic analysis (FFPE block)
• Patient under administrative, judicial decision or AME (State Medical Aid)

Sponsors & Collaborators

• Centre Jean Perrin: lead

Study Sites (1)

Centre Jean Perrin

Clermont-Ferrand, PUY DE DOME, 63001, France

RECRUITING

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Tressie HERRMANN, MD

  Centre Jean Perrin

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Judith PASSILDAS JAHANMOHAN, PhD

CONTACT

0463663337; judith.passildas@clermont.unicancer.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: It is a single-centre study with a prospective part (living patients) and a retrospective part (deceased patients) involving data collection via the patient's medical software. A molecular analysis on histological blocks taken at the time of diagnosis will be carried out as part of the study. This analysis may potentially generate new genomic data to classify patients with ovarian cancer. Could result in the incidental discovery of abnormalities, which may eventually modify the management of the patient, notably her monitoring and screening for other pathologies. No additional sampling will be carried out as part of the study.

Study Record Dates

• First Submitted: November 28, 2025
• First Posted: January 23, 2026
• Study Start: January 22, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)